Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
Cariprazine is currently approved for the treatment of patients with schizophrenia (USA and EU), and for manic, depressive, and episodes with mixed features in bipolar I disorder (USA): several randomized controlled studies have also explored its efficacy in patients with major depressive disorder....
Guardado en:
Autores principales: | Borjanka Batinic, Ivan Ristic, Milica Zugic, David S. Baldwin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/75c9ae4a9cf5413babeb8d494ee13cd4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Update on schizophrenia and bipolar disorder: focus on cariprazine
por: Roberts RJ, et al.
Publicado: (2016) -
Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
por: Aleksandr M. Reznik, et al.
Publicado: (2020) -
Development and Structures of Trialogue for Bipolar Disorders in Germany and Guidelines of the German Society for Bipolar Disorders
por: Martin Schaefer, et al.
Publicado: (2021) -
Evaluación de la calidad de vida de pacientes bipolares chilenos: propiedades psicométricas y utilidad diagnóstica de la versión chilena del cuestionario Quality of Life Bipolar Disorder (QoL.BD-CL)
por: Morgado,Carolina, et al.
Publicado: (2015) -
New drugs in psychiatry - cariprazine, lurasidone, esketamine
por: Pożarowska Kinga, et al.
Publicado: (2021)